ImmunovantIMVT
$34.2-2.5%11월 13일 종가 기준
시가총액 $7.1B
3달 전보다 -15.2%
최고 $44.96최저 $26.73
세로선 = 임상·딜 이벤트 · 차트 위에서 스크롤하면 확대·축소, 확대 중엔 가로로 넘겨볼 수 있어요
지켜보기 의견AI 점수 65 / 100
진행 중인 임상과 AI 예측
- Phase 2IMVT-1402 만성 염증성 탈수초성 다발신경병증 임상모집 중IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)71%
- Phase 2IMVT-1402 그레이브스 갑상선 질환 장기 임상진행 중A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)71%
- Phase 2IMVT-1402 성인 그레이브스병 치료 임상모집 중A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease71%
- Phase 2IMVT-1402 성인 그레이브스병 치료 임상모집 중A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease71%
- Phase 2중증 쇼그렌 증후군 환자 대상 IMVT-1402 치료 효과 임상모집 중Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity71%
- Phase 3IMVT-1402 전신 중증 근무력증 유효성 평가 임상모집 중Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis59%
- Phase 2IMVT-1402 난치성 류마티스 관절염 임상진행 중A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis75%
- Phase 2IMVT-1402 피부 루푸스 치료 임상모집 중A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)87%
- Phase 3바토클리맙 성인 전신성 중증근무력증 3상 임상진행 중Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis59%
- Phase 2바토클리맙 만성 염증성 신경병증(CIDP) 연장 임상진행 중An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)71%
- Phase 2바토클리맙 만성 염증성 신경병증(CIDP) 치료 임상진행 중To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP71%
- Phase 3갑상선 안병증 환자 대상 바토클리맙 연장 임상진행 중Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease59%
성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.